XORTX Therapeutics Return On Equity vs. Current Valuation

XRTX Stock   1.89  0.14  8.00%   
Based on XORTX Therapeutics' profitability indicators, XORTX Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in January. Profitability indicators assess XORTX Therapeutics' ability to earn profits and add value for shareholders.
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
(0.47)
Current Value
(0.49)
Quarterly Volatility
3.23989174
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, XORTX Therapeutics' Payables Turnover is fairly stable compared to the past year. Income Quality is likely to climb to 2.37 in 2024, whereas Book Value Per Share is likely to drop 1.66 in 2024.
For XORTX Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of XORTX Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well XORTX Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between XORTX Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of XORTX Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist.
For more information on how to buy XORTX Stock please use our How to Invest in XORTX Therapeutics guide.
Please note, there is a significant difference between XORTX Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if XORTX Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XORTX Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

XORTX Therapeutics Current Valuation vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining XORTX Therapeutics's current stock value. Our valuation model uses many indicators to compare XORTX Therapeutics value to that of its competitors to determine the firm's financial worth.
XORTX Therapeutics is rated first in return on equity category among its peers. It is rated first in current valuation category among its peers . At this time, XORTX Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the XORTX Therapeutics' earnings, one of the primary drivers of an investment's value.

XORTX Current Valuation vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

XORTX Therapeutics

Return On Equity

 = 

Net Income

Total Equity

 = 
-0.29
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

XORTX Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
2.96 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

XORTX Current Valuation vs Competition

XORTX Therapeutics is rated first in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 20.51 Trillion. XORTX Therapeutics adds roughly 2.96 Million in current valuation claiming only tiny portion of equities under Health Care industry.

XORTX Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in XORTX Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, XORTX Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of XORTX Therapeutics' change in net profit over the period of time. It can combine multiple indicators of XORTX Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Net Loss-8.5 M-8.1 M
Net Interest Income253.5 K266.2 K
Operating Income-6 M-5.7 M
Net Loss-2.2 M-2.3 M
Income Before Tax-2.2 M-2.3 M
Total Other Income Expense Net3.6 M3.8 M
Net Loss-2.2 M-2.3 M
Interest Income255.2 K196.1 K
Change To Netincome-4.1 M-3.9 M
Net Loss(1.44)(1.52)
Income Quality 2.26  2.37 

XORTX Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on XORTX Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of XORTX Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the XORTX Therapeutics' important profitability drivers and their relationship over time.

Use XORTX Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if XORTX Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in XORTX Therapeutics will appreciate offsetting losses from the drop in the long position's value.

XORTX Therapeutics Pair Trading

XORTX Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to XORTX Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace XORTX Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back XORTX Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling XORTX Therapeutics to buy it.
The correlation of XORTX Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as XORTX Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if XORTX Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for XORTX Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your XORTX Therapeutics position

In addition to having XORTX Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Corona Opportunity Thematic Idea Now

Corona Opportunity
Corona Opportunity Theme
Firms that are involved in some capacity in making products or providing services to the public to buttle the virus directly or indirectly. This also includes some defencive and contrarian stocks and ETFs that are managing to avoid the big market correction coused by coronavirus. The Corona Opportunity theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corona Opportunity Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for XORTX Stock Analysis

When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.